Eli Lilly Says Their Obesity Pill led to More Than 12% Weight Loss in Late

INDIANAPOLIS–Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval.

Patients taking the pill called orforglipron, an oral GLP-1 receptor, lost almost 12% of their body weight, or roughly 27 pounds, at 72 weeks, study results show. The highest dose of the pill helped nearly 60% of patients lose 10% or more of their body weight.

In addition to weight loss, orforglipron also led to reductions in cholesterol, triglycerides, and blood pressure.

“With orforglipron, we’re working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments,” Kenneth Custer, Ph.D., execut